VIVS

VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool integrates its proprietary NAMkind™ ileum and colon tissues with advanced machine‑learning analytics to identify drug‑induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process VivoSim has named VitroSense™. The model was built using a training set of dozens of compounds. Using high-quality real-world 3d NAM assay results generated from the set of training compounds, the model attained a predictive accuracy of 96% for potential diarrhea. This success represents a significant step forward for the field, demonstrating the value of combining data from VivoSim’s complex 3D cell-based assays with machine learning approaches. For a novel compound being investigated for the first time, such as from a client, multiple data endpoints are measured in NAMkind™ intestine assays and these data are fed into the AI prediction model to generate an overall assessment of diarrhea risk. Because so many cancer drugs have dose-limiting toxicities, the Company believes that this breakthrough over reliance on animal models can have a transformational impact on the next generation of cancer treatments. VitroSense™ – the use of NAMkind™-produced data to train predictive machine learning models Central to the concept of use of NAMkind™ models in this way is its integration with its proprietary VitroSense™ toolkit that generates trained machine language models using data from its highly relevant human cell NAMkind™ tissues. “The high biological fidelity of NAMkind™ models allows us to generate data in line with what is seen in humans” said Keith Murphy, VivoSim Executive Chairman. “By using that high-quality data to train AI models, we get much more accurate predictions. You’ve heard of “garbage in, garbage out”, but our models are the opposite: Golden raw data from NAMkind™ tissue assays is fed to the VitroSen...

SHANGHAI, Feb. 05, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced a profit alert for the fourth quarter of 2025. The board of directors of the Company (the “Board”) wishes to inform shareholders and potential investors that, based on a preliminary assessment of the Company’s unaudited consolidated management accounts and the information currently available to the Board, the Company is expected to achieve an adjusted profit from operations (non-GAAP) in the range of approximately RMB700 million (approximately US$100 million)i to RMB1,200 million (approximately US$172 million) for the fourth quarter of 2025, which is defined as profit from operations excluding share-based compensation expenses, representing the first time the Company has recorded an adjusted profit from operations (non-GAAP) on a quarterly basis. In comparison, the Company recorded an adjusted loss from operations (non-GAAP) of RMB5,543.6 million in the fourth quarter of 2024. The expected adjusted profit from operations (non-GAAP) for the fourth quarter of 2025 was primarily attributable to (i) the Company’s sustained growth in sales volume in the fourth quarter of 2025; (ii) the optimization of vehicle margin driven by a favorable product mix; and (iii) the Company’s ongoing comprehensive cost reduction efforts and continued improvement in operational efficiency. In addition, under the GAAP measures, the Company is expected to record a profit from operations of approximately RMB200 million (approximately US$29 million) to RMB700 million (approximately US$100 million) for the fourth quarter of 2025. As of the date of this press release, the Company is in the process of preparing and finalizing the financial results for the three months and full year ended December 31, 2025 (the “Q4 and FY2025 Results”). The information contained in this press release is only based on a preliminary review of the unaudited consolidated management accounts and the information currently available to the Board, and is not based on any figures or information which have been audited or reviewed by the Company’s independent auditor or the audit committee of the Board. The above data may therefore differ from the figures to be disclosed in the audited or unaudited consolidated fin...

NIO Inc. NIO, XPeng Inc. XPEV and Li Auto LI, three major China-based smart electric vehicle manufacturers, recently released their delivery figures for December 2025 and the fourth quarter of 2025. NIO reported a record 48,135 vehicle deliveries in December 2025, marking a 54.6% year-over-year increase. This total included 31,897 units from its premium NIO brand, 9,154 units from the family-focused ONVO brand and 7,084 units from the compact high-end FIREFLY brand. Fourth-quarter deliveries reached a new high of 124,807 vehicles, up 71.7% from the prior year. For full-year 2025, NIO delivered 326,028 vehicles, rising 46.9% year over year, while cumulative deliveries stood at 997,592 units as of Dec. 31, 2025. XPeng delivered 37,508 vehicles in December 2025, representing a modest 2% year-over-year increase. Total deliveries for 2025 surged to 429,445 units, more than doubling from the previous year with a 126% increase. Overseas deliveries for the year totaled 45,008 vehicles, up 96% year over year, as XPeng expanded operations to 60 countries and regions by the end of 2025. Li Auto delivered 44,246 vehicles in December 2025 compared with 58,513 units in the same month of 2024. Fourth-quarter deliveries amounted to 109,194 vehicles, bringing cumulative deliveries to 1,540,215 units as of Dec. 31, 2025. During the year, Li Auto broadened its international presence by launching the Li L9, Li L7 and Li L6 models in Egypt, Kazakhstan and Azerbaijan, marking the entry into markets across Central Asia, the Caucasus and Africa. By year-end, the company operated 548 retail stores in 159 cities, along with 561 service centers and authorized body and paint shops across 224 cities. It also had 3,907 supercharging stations in China, comprising 21,651 charging stalls. While shares of NIO and XPeng have rallied 10.2% and 73.2%, respectively, over the past year, shares of LI have plunged 31.6%. Image Source: Zacks Investment Research NIO, XPEV & LI carry a Zacks Rank #3 (Hold) each at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIO Inc. (NIO) : Free Stock Analysis Report Li Auto Inc. Sponsored ADR (LI) : Free Stock Analysis Report XPeng Inc. Sponsored ADR (XPEV) : Free Stock...

Company Achieved New Record-High Monthly and Quarterly Deliveries 34,749 vehicles were delivered in September 2025, increasing by 64.1% year-over-year 87,071 vehicles were delivered in the three months ended September 2025, increasing by 40.8% year-over-year Cumulative deliveries reached 872,785 as of September 30, 2025 SHANGHAI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its September and third quarter 2025 delivery results. The Company delivered 34,749 vehicles in September 2025, reaching a new monthly record and representing an increase of 64.1% year-over-year. The deliveries consisted of 13,728 vehicles from the Company’s premium smart electric vehicle brand NIO, 15,246 vehicles from the Company’s family-oriented smart electric vehicle brand ONVO, and 5,775 vehicles from the Company’s small smart high-end electric car brand FIREFLY. The Company delivered 87,071 vehicles in the third quarter of 2025, reaching a new quarterly high and representing an increase of 40.8% year-over-year. Cumulative deliveries reached 872,785 as of September 30, 2025. On September 20, 2025, NIO’s flagship premium SUV, the All-New ES8, was officially launched, with user deliveries starting shortly after. Built upon NIO’s decade-long technological achievements, the All-New ES8 represents the pinnacle of the latest smart EV technologies and is well positioned to lead large three-row SUVs into the battery electric era. Setting a new benchmark for the premium large three-row battery electric SUVs, the All-New ES8 offers users a refined, safe, and seamless experience on every journey towards a new horizon. About NIO Inc. NIO Inc. is a pioneer and a leading company in the global smart electric vehicle market. Founded in November 2014, NIO aspires to shape a sustainable and brighter future with the mission of “Blue Sky Coming”. NIO envisions itself as a user enterprise where innovative technology meets experience excellence. NIO designs, develops, manufactures and sells smart electric vehicles, driving innovations in next-generation core technologies. NIO distinguishes itself through continuous technological breakthroughs and innovations, exceptional products and services, and a community for shared growth. NIO provides premium smart e...

Two of China’s biggest noted vehicle makers, NIO Inc. NIO and Li Auto LI, are about to report their second-quarter 2025 results. Li Auto will release its numbers this Thursday, while NIO will follow next Tuesday. Ahead of their results, the question is: Which of these two EV players looks better positioned right now? Li Auto has built its success on a hybrid approach. Its extended-range electric vehicles (EREVs) combine EV benefits with the reassurance of a gasoline-powered generator, easing range anxiety for Chinese drivers. The company’s popular L-series — L6, L7, L8 and L9 — has captured strong demand. Li also ventured into pure battery EVs with the MEGA last year, while recently adding the Li i8, a six-seat family SUV, to its lineup. Another model, the Li i6, is expected to debut soon. NIO, on the other hand, has gone all-in on pure EVs. Its portfolio includes a broad range of sedans and SUVs such as the ES6, ES8, EC6, ET5, ET7 and ET9. The company is also set to launch its redesigned ES8 later this year. Beyond the NIO brand, NIO is expanding with ONVO, its mass-market division, which has already launched the L60 and L90, with a third model on the way. Its premium small car brand, Firefly, started deliveries in April. This three-pronged strategy highlights NIO’s ambition to capture different segments of the EV market. In terms of sheer numbers, Li Auto continues to outpace NIO. For the second quarter of 2025, Li delivered 111,074 vehicles, while NIO delivered 72,056. However, the growth picture tells a different story. Li’s deliveries were only up 2.3% year over year, suggesting demand is stabilizing. Meanwhile, NIO’s deliveries surged 25.6% compared to last year, signaling a stronger momentum shift in its favor. Margins are a critical measure of EV makers’ financial health. NIO’s vehicle margin climbed to 10.2% in the first quarter of 2025, an improvement from 9.2% a year ago. The gain was driven by better scale, lower costs per unit and stronger efficiency in its supply chain. Li Auto remains ahead in this metric. Its vehicle margin stood at 19.8% in the first quarter, slightly up from 19.3% in the prior year. The company’s ability to maintain high margins speaks of its cost discipline and pricing power. For now, Li holds the edge on profitability. The balance sheet comparison tilts in Li Auto’s favor. As of March 31, 2025, Li Auto held about $15.3 bi...

SAN DIEGO (AP) — SAN DIEGO (AP) — VivoSim Labs, Inc. (VIVS) on Tuesday reported a loss of $2.8 million in its fiscal first quarter. On a per-share basis, the San Diego-based company said it had a loss of $1.14. The development-stage company focused on commercializing functional human tissue for drug and biological research posted revenue of $37,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VIVS at https://www.zacks.com/ap/VIVS

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases – inclusive of classic cases of “liver tox misses” drugs with unforeseen liver toxicity found in clinical trials or drugs that were withdrawn from the market after liver toxicity issues emerged later. The platform identified correctly that 87.5% of the known liver-toxic drugs could be seen as liver toxic using NAMkind™ liver. This is known as the sensitivity of the platform, which at 87.5% is a world’s best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform. VivoSim’s NAMkind™ liver model is a physical organoid wet lab model of liver made using cells from human donors. VivoSim is also developing what it believes will be industry-best in silico predictions of liver tox. Artificial intelligence (AI) models in VivoSim’s NAMkind™ services suite will be trained on extensive set of proprietary, real-world data from organoid models made from human donor cells, giving much richer and more extensive information than is possible with data from human clinical trials. VivoSim offers liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA’s push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim’s market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. VivoSim has the capability to help transform the way drug development is done. By substantially reducing failures in clinical trials, the company believes it can help reduce the cost of development per approved drug by 50% across the industry. As a result of the inability to fully predict liver tox...